Who Will Be The First To Get A Psychedelic Drug Through The FDA To Commercialization?Psyched Wellness Is Laser Focused On Bringing Truly Differentiated Mushroom Products To MarketAtai Life Sciences: The Next Unicorn Of The Psychedelics SectorATAI Life Sciences Announces Closing of $125 Million Series C Financing RoundRritual Mushrooms Is Pioneering The Future Of Functional FoodsMindMed’s Drug Delivery Business Is One That Psychedelic Sector Investors Need To Be WatchingPure Extracts Technologies Corporate UpdateNova Mentis Life Science Announces Receipt of Pilz Shareholder ApprovalField Trip Health Ltd. Announces Expansion to The Netherlands and Launch of Proprietary Truffle ProgramPsyched Wellness Ltd. Announces Insider Buying and Option Grant to Professor NuttMindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial froTryp Appoints Dr. Jim Gilligan, PhD, MBIS, as President and Chief Scientific OfficerHavn Life Announces Launch of a Range of Natural Health ProductsCybin Corp. Will Make Its Debut Today On The NEO Under The Symbol “CYBN”Tryp Therapeutics Has “The Right Stuff” To Bring Psychedelic Therapies Through To CommercializationMindset Pharma Closes Ontario Brain Institute Funding and Announces Private Placement OfferingNuminus Wellness Is Executing Flawlessly On Their B2B Strategy via Numinus BiosciencesEntheon Biomedical Corp. (formerly MPV Exploration Inc.) Announces Completion of Amalgamation and Final Approval from thCybin Completes Reverse Take-Over TransactionThe Psychedelic Sector Is Getting A Major Momentum Boost Post U.S. Election

Technical420 Site Search

Returned 4 result(s).

The Psychedelic Sector Is Getting A Major Momentum Boost Post U.S. Election

The US election proved to be a catalyst for the psychedelic therapy industry after two major ballot initiatives were passed in the District of Columbia and in Oregon. According to the Associated Press, D.C. voters passed legislation that would make the possession and use of certain psychedelic plants the lowest…

3 Psychedelic Stocks With The Highest Chance Of Successfully Bringing A Psychedelic Therapy To Market

One of the most exciting growth stories in the biotech sector relates to the studies on psychedelic substances. The companies that focus on this vertical are working to develop treatments for mental illness. We are bullish on this opportunity due to the size of the total addressable market (TAM). Although…

Cybin Corp. Is A Best In Class Psychedelics Company When Compared To Industry Bellwether Compass Pathways

Last week, Compass Pathways (CMPS) commenced trading on the Nasdaq and became the first psychedelic drug company to go public on a major U.S. stock exchange. When Compass filed to go public, the deal generated substantially more interest from investors than expected. As a result, the psychedelic therapy company upsized…

Compass Pathways Is Set To Take Psychedelics Mainstream With An IPO On The Nasdaq

2020 has been a banner year for the psychedelic sector and we believe that the industry is in the early stages of a major growth cycle. Last week, Compass Pathways announced a major milestone and filed to go public on the Nasdaq Global Market under the symbol CMPS. The leading…

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link